Evidence map›Paper›PMID 38257765›Full record

ArticleViruses2023

Structural Basis for the Inhibition of SARS-CoV-2 M

Zhenyu Zhao, Qinyao Zhu, Xuelan Zhou, Wenwen Li, Xiushan Yin, Jian Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zhenyu ZhaoCollege of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China.
Qinyao ZhuApplied Biology Laboratory, College of Pharmaceutical and Biological Engineering, Shenyang University of Chemical Technology, Shenyang 110142, China.
Xuelan ZhouCollege of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China.ORCID 0009-0007-8138-1923
Wenwen LiCollege of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China.
Xiushan YinApplied Biology Laboratory, College of Pharmaceutical and Biological Engineering, Shenyang University of Chemical Technology, Shenyang 110142, China.
Jian LiCollege of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China.
Gannan Medical University · CNShenyang University of Chemical Technology · CN

Funding

Jiangxi Key Research and Development Program 20203BBG73063Jiangxi Natural Science Foundation for Distinguished Young Scholars 20212ACB216001National Natural Science Foundation of China (82360701)
6 · The paper itself

Abstract

Preventing the spread of SARS-CoV-2 and its variants is crucial in the fight against COVID-19. Inhibition of the main protease (M

Indexed as

Coronavirus 3C ProteasesNaphthoquinonesSARS-CoV-2LactamsLeucineNitriles3C-like proteinase, SARS-CoV-2Coronavirus 3C ProteasesLactamsLeucineNaphthoquinonesNitrilesshikoninmain proteaseMpro inhibitormutantPF-07321332SARS-CoV-2shikonin

Identifiers

PMID38257765
PMCPMC10818409
OpenAlexW4390470827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.